Inogen (INGN) Q3 2025: International B2B Soars 19%, Cementing Global Expansion Pillar
International B2B momentum and disciplined operating execution defined Inogen's quarter, with seven consecutive periods of mid-single-digit growth solidifying the turnaround narrative. Management’s focus on expanding the global footprint and innovating the product lineup is reshaping the company’s competitive position in the respiratory care market. With EBITDA guidance raised and a new product cycle underway, investors face a business transitioning from stabilization to targeted growth levers in 2026.
Summary
- Global Channel Acceleration: International B2B growth outpaced expectations, reinforcing the shift from domestic reliance.
- Profitability Inflection: Operational discipline yielded consecutive quarters of positive adjusted EBITDA and improved cash flow.
- Product Pipeline Expansion: New launches and a broader portfolio set the stage for future addressable market gains.
Performance Analysis
Inogen delivered its seventh straight quarter of mid-single-digit revenue growth, with total revenue reaching $92.4 million, a 4% year-over-year increase. This performance was powered by a 19% surge in international B2B sales, now accounting for a substantial share of the business, and a solid 6.6% gain in domestic B2B. The company’s direct-to-consumer (DTC) channel, DTC, direct sale to end-users, contracted by nearly 18% as leadership intentionally streamlined the model to drive efficiency and profitability, signaling a deliberate recalibration rather than market share loss.
Gross margin declined by 182 basis points to 44.7%, largely due to the growing B2B mix and a one-time logistics-related adjustment that weighed on rental margins. Operating expenses were tightly managed, down 1.4% year-over-year, supporting a third consecutive quarter of positive adjusted EBITDA at $2.3 million. Cash flow from operations was positive, and the balance sheet remains unlevered with $124.5 million in cash equivalents.
- International B2B Expansion: 19% YoY growth, with momentum from both existing and new markets, especially in Europe.
- DTC Channel Reset: Nearly 18% decline reflects the shift toward a leaner, more profitable direct model.
- Rental Margin Drag: One-time logistics costs and lower reimbursement rates compressed rental profitability, though headwinds are stabilizing.
Leadership’s reiteration of full-year revenue guidance and an upward revision of EBITDA expectations signals confidence in the underlying business trajectory despite channel and margin headwinds.
Executive Commentary
"Continued market conversion from portable oxygen tanks to POCs fueled year-over-year unit growth of more than 15%, reflecting steady execution and increasing market adoption. International B2B was a standout contributor achieving 19% year-over-year growth as we advanced our strategy to expand into high opportunity global markets."
Kevin Smith, President and Chief Executive Officer
"Total gross margin was 44.7% in the third quarter of 2025, decreasing 182 basis points from the same period in the prior year, primarily driven by increased business-to-business sales as a percentage of total revenue... For the full year of 2025, we are now raising adjusted EBITDA to approximately $2 million."
Mike Bork, Chief Financial Officer
Strategic Positioning
1. International B2B as a Growth Engine
International B2B is now the company’s fastest-growing segment, with 19% year-over-year growth in Q3 and a clear runway for continued expansion. Management clarified that this growth was broad-based, not the result of a single large tender, and primarily driven by share gains in existing European markets. Expansion into new geographies is ongoing, with China flagged as a major future opportunity as regulatory and partnership groundwork continues.
2. Product Portfolio Diversification
The launch of Voxy5, stationary oxygen concentrator, marks a significant step in portfolio breadth, enabling Inogen to address approximately 90% of the oxygen therapy market that requires stationary units. Early sales have begun, but material contribution is expected in 2026 and beyond, with management emphasizing the strategic importance of offering both portable and stationary solutions to deepen DME, durable medical equipment, relationships and market reach.
3. Operational Discipline and Profitability Trajectory
Cost structure management remains a core focus, as evidenced by reduced operating expenses and consecutive quarters of positive adjusted EBITDA. Management’s ability to deliver operating leverage while investing in R&D and commercialization (notably for Semiox, bronchial decongestion device) demonstrates a maturing business model with improved cash flow dynamics and a stronger foundation for scaling new product launches.
4. Innovation Pipeline and Reimbursement Pathways
Semiox’s limited US market release and ongoing clinical trials in Europe and China reflect a deliberate, staged approach to market development and reimbursement. Management is prioritizing evidence generation and physician engagement to support future high-margin revenue streams as reimbursement is secured in key markets.
Key Considerations
This quarter’s results highlight a business in the midst of a strategic transformation, with global channel diversification and innovation as key levers. Investors should weigh the following considerations as Inogen enters a new phase of execution:
Key Considerations:
- Channel Mix Shift: The pivot toward B2B, especially internationally, is structurally lowering gross margin, but improving revenue stability and scale potential.
- Portfolio Expansion Timing: Voxy5’s impact will be more pronounced in 2026, with groundwork laid this year for broader adoption.
- Reimbursement Risk: Semiox’s commercial ramp hinges on successful reimbursement approvals, particularly in the US and Europe.
- Cash Flow Resilience: Positive operating cash flow and a debt-free balance sheet provide flexibility for further R&D and market expansion.
Risks
Gross margin compression remains a risk as B2B outpaces higher-margin channels, and one-time cost adjustments may recur in logistics or rental operations. Timing and success of reimbursement for new products like Semiox are uncertain, and international expansion exposes Inogen to regulatory, competitive, and currency risks. Guidance assumes stabilization in DTC and no material tariff impact, both of which require ongoing monitoring.
Forward Outlook
For Q4 2025, Inogen guided to:
- Revenue of $87 million to $90 million, implying approximately 10% year-over-year growth at the midpoint.
For full-year 2025, management raised guidance:
- Adjusted EBITDA of approximately $2 million (from prior breakeven expectation).
Management highlighted several factors that will shape results:
- Continued execution in international B2B and the Voxy5 launch are key upside levers.
- DTC channel stabilization and timing of large international orders remain variables to watch.
Takeaways
Inogen’s quarter underscores a successful pivot toward international B2B and operational discipline, with innovation and global expansion as the next growth catalysts.
- Global Channel Diversification: International B2B is now a clear growth engine, reducing reliance on US channels and broadening market opportunity.
- Profitability and Cash Flow: Adjusted EBITDA and cash generation signal a more resilient business, with cost controls offsetting margin headwinds.
- Product Cycle and Innovation: The Voxy5 launch and Semiox’s staged rollout are building blocks for future revenue streams, but timing and reimbursement milestones will be critical for upside realization.
Conclusion
Inogen’s Q3 2025 results validate its turnaround strategy, with consistent revenue growth, international channel momentum, and improved profitability. The company is positioned to capitalize on a larger addressable market, but execution on new product launches and reimbursement will define the next phase of value creation.
Industry Read-Through
Inogen’s strong international B2B growth and portfolio expansion signal a broader trend in respiratory care: companies that can diversify channels and innovate toward home-based solutions are best positioned for secular growth. The shift from DTC to B2B and the focus on reimbursement for novel devices reflect pressures and opportunities facing all medtech players in chronic care markets. Margin compression from channel mix shifts is likely to persist across the sector, but those with operational discipline and robust innovation pipelines will be best equipped to sustain growth as global health systems prioritize home-based therapies.